Efficacy of immunotherapy and prognosis in anti-LGI1 encephalitis patients: A meta-analysis.

ABSTRACT:

Objective

To assess the efficacy and safety of immunotherapy for LGI1 antibody encephalitis, and consider the predictors of poor outcomes following immunotherapy.

Methods

We searched PubMed and Embase for articles reporting the immunotherapy data of anti-LGI1 encephalitis patients. The proportions of patients with poor outcomes (modified Rankin Scale [mRS] score > 2) at 3 months, 12 months, and the last follow-up, as well as the odds ratio [OR] of predictors were pooled.

Results

The review included 162 articles with 1066 patients. The proportion of patients with poor functional outcomes was 21% at 3 months, 14% at 12 months, and 14% at the last follow-up after receiving immunotherapy. The proportion of patients with reported relapse was 16.6%. The mean duration from o

SUBMITTER: Kong X 

PROVIDER: S-EPMC10502619 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature